PDCD1 and melanoma: The S3 subgroup exhibited significant similarity to melanoma responders, suggesting a promising likelihood of sensitivity to anti-PD-1 therapy (Bonferroni-corrected p = 0.048, Supplementary Figure S3 A; nominal p = 0.004, Supplementary Figure S3B).